Mucopolysaccharidosis or mucopolysaccharidosis-like disorder
MONDO:0100365Any disease that presents as a mucopolysaccharidosis or mucopolysaccharidosis-like disorder.
62 clinical trials for this condition and its sub-types, 0 tagged with Mucopolysaccharidosis or mucopolysaccharidosis-like disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mucopolysaccharidosis or mucopolysaccharidosis-like disorder
-
Mucopolysaccharidosis 14 trials · 62 incl. sub-types
8 sub-types
- Mucopolysaccharidosis type 2 25 trials Sub-types →
- Mucopolysaccharidosis type 3 7 trials · 18 incl. sub-types Sub-types →
- Mucopolysaccharidosis type 1 11 trials · 16 incl. sub-types Sub-types →
- Mucopolysaccharidosis type 4 2 trials · 10 incl. sub-types Sub-types →
- Mucopolysaccharidosis type 6 8 trials Sub-types →
- Mucopolysaccharidosis type 7 8 trials
- Mucopolysaccharidosis type 9 1 trial
- Mucopolysaccharidosis, type 10 0 trials
-
Mucopolysaccharidosis-plus syndrome 0 trials
Most studied deeper sub-types
-
Early enzyme therapy may help kids with rare disease grow better
Disease control CompletedThis study followed 21 boys with Hunter syndrome who started taking Elaprase before age 6. Researchers tracked their height and weight for at least 5 years to see if the drug helps them grow more like other children. The study also monitored safety and compared growth data to unt…
Phase 4 • Sponsor: Shire • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Hunterase extended trial shows promise for managing hunter syndrome
Disease control CompletedThis study looked at the long-term safety and effectiveness of Hunterase (idursulfase beta) in 30 people with Hunter syndrome over about one year. Participants had either completed a previous phase 3 study or had used Hunterase for at least six months. The goal was to monitor sid…
Phase 3 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Enzyme therapy shows promise for rare disease in china
Disease control CompletedThis study tested a drug called Aldurazyme (laronidase) in 12 Chinese people with mucopolysaccharidosis I (MPS I), a rare genetic disorder. Participants received weekly infusions for 26 weeks to see if the treatment is safe and reduces waste products in urine. The goal is to mana…
Phase 4 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 26, 2026 18:08 UTC
-
Massive MPS i registry sheds light on rare disease
Knowledge-focused CompletedThis registry tracked over 1,400 people with MPS I, a rare genetic disorder, to better understand how the disease progresses and how treatments like enzyme replacement therapy work over time. It did not test a new drug but collected real-world data to help doctors improve patient…
Sponsor: Genzyme, a Sanofi Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Dexmedetomidine may shield blood vessels in nose jobs
Knowledge-focused CompletedThis completed study looked at whether the sedative dexmedetomidine can protect blood vessel lining during rhinoplasty. 90 patients received either standard anesthesia or dexmedetomidine plus anesthesia. Researchers measured two blood markers of vessel damage to see if dexmedetom…
Phase 4 • Sponsor: Firat University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Could a single DNA test solve the mystery of rare brain diseases in kids?
Knowledge-focused CompletedThis study looked at whether whole genome sequencing (a complete read of a person's DNA) can help diagnose leukodystrophies, a group of rare brain diseases that are hard to identify. Researchers enrolled 236 children with white matter abnormalities on brain scans but no known gen…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Rare disease mystery unraveled: 5-Year study tracks atypical morquio a
Knowledge-focused CompletedThis study followed 7 adults with a milder form of Morquio A disease for 5 years to learn how the condition changes over time. Researchers measured walking ability and other health factors to better understand the disease and improve future treatment evaluations. The goal was to …
Sponsor: GOIZET • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC